I agree. Check this out also. Trend reversal soon. Google search Eros – A Vicious Takedown by a Professional ?
Last week SEC was informed about the con artists in fake company named Grid Petroleum. Some of their projects they claim to going on from 2010 on wards with one month deadline with drilling status which never happened. Lot of novice players lost interest. IR has fooled last few months another set of new investors after "DTC chill" lifted. Now IR has gone complete silent mode. They don't even pick up phone or answer basic questions. This company is running on fake news for over 7 years now. Finally SEC will track it down very very soon. I am so happy this will be over soon.
It is time to put stop to con artists Tim Dehererra and his associates. Finally we ere able to contact SEC and report all the violations in detail. SEC will wind down this company soon.
cozamanisdion, 5 stars to your post. I agree... this company has huge potential short and long term. Hold and prosper....patience is the key here.
Cell & Gene Therapy Forum
January 28-30th, 2013
The preeminent industry led meeting place pushing the maturation of regulatory, manufacturing, R&D and commercial strategies. Delivering the information and contacts you need to drive your cell and gene therapy products forward.
Phacilitate's 9th Annual Cell & Gene Therapy Forum is firmly established as the world’s leading strategy and partnering event for senior decision makers from the global cell therapy, gene therapy and tissue engineered product sectors.
The Cell & Gene Therapy Forum 2013 offers:
More senior big pharma and big biotech representatives than ever before – both senior scientists and business development cheque-writers seeking partnering opportunities
More key regulators and other regulatory experts from the US, Europe and Asia Pacific
More public and private sector investors, including emerging alternative players as well as the more traditional funding sources such as VCs and the NIH
And of course, more CXO-level representatives of the world’s leading cell & gene therapy biotech companies
The Cell & Gene Therapy Forum is held along side the Vaccine Forum and the Protein Therapeutics Forum. Attendees have unlimited access to all 3 conferences.
To contribute your views to the development of the 2012 program, please email firstname.lastname@example.org.
For sponsorship and booth information, please also email email@example.com.
Don't let these daily PPS ups and downs scare you. What is important is this science works and have tremendous potential short and long term. The results were really impressive:
From the demo....
The data produced comparing optimal doses to the SNc of MANF = 10 µg and GDNF = 10 µg in this model indicate the following at four weeks post-treatment:
1.MANF reduced behavioral deficits by 53%, whereas behavioral deficits with GDNF increased by 20%;
2.MANF produced a 14.4% reinnervation of the striatum, whereas striatum innervation with GDNF was reduced by 9.9%;
3.MANF increased dopamine concentrations in the striatum, whereas striatum dopamine concentrations with GDNF did not increase.
“We are excited about our results with MANF as we have demonstrated superiority to GDNF in a number of key areas related to recovery of function in Parkinson’s disease,” added Dr. Joseph Rubinfeld, Amarantus advisor and Amgen Co-Founder . “We intend to continue to move our Parkinson’s program forward, while also evaluating other disease indications for MANF with potentially accelerated regulatory pathways, including certain orphan diseases. This strategy may significantly reduce MANF’s overall time to market versus a Parkinson’s-only strategy.”
In the study, rodents were lesioned with 6-OHDA on one side of their brain (t = 0). Behavior was tested for baseline (t =1 week) and vehicle, MANF (3 µg, 10 µg or 36 µg) and GDNF (10ug) were injected in different groups of animals at t = 2 weeks. Behavior was tested for drug effect at t = 4 weeks (2 weeks post-treatment) and at t = 6 weeks (4 weeks post-treatment).
The behavioral data achieved statistical significance with a p value of less than 0.03 with animal groups of N=12. The striatum reinnervation data and dopamine concentration data did not achieve statistical significance because the animals sacrificed from the behavioral study were divided into 2 separate groups of N=6 for the analysis of densitometry (striatum reinnervation) and neurochemistry (dopamine concentration in the striatum). The method of analysis of the rat brains did not allow for the densitometry and neurochemistry to be analyzed simultaneously in the same animals, leading to groups of N = 6 or less, which was insufficient to achieve statistical significant.
The Company believes the data are positive, even without statistical significance due to small groups of animals in the densitometry and chemistry data, because there are consistent internal results correlating behavior, stereology, densitometry and neurochemistry, most notably at MANF = 10 µg and GDNF = 10 µg. The Company is preparing to initiate IND enabling studies for MANF as a disease-modifying drug candidate for Parkinson’s disease.
MANF treatment for parkinson is 3 Billion dollars market value worldwide. More than one billion in US itself. This is the future and I am glad to be in this stock under 20 cents. Next week on wards 20 cents PPS will be history. We can easily surpass 50 cents to $1 depending on data. Listen to the video on their website. CEO Gerald knows what he is talking about. This is a huge investment opportunity!
In a document prepared for Thursday's meeting, Hemispherx said, "we believe that the preponderance of the data clearly provide substantial evidence of [effectiveness] and reasonable safety for this product for the target population of CFS patients." FDA's advisory panel is being asked to vote on whether it thinks Ampligen is safe and effective as well as to vote on whether it thinks the product should be approved. The FDA usually follows the recommendations of its advisory panels but is not required to.